Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

First cannabis-based medicine for childhood epilepsy approved

A cannabidiol oral solution for use as adjunctive therapy of childhood seizures is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA).

A cannabidiol oral solution for use as adjunctive therapy of childhood seizures is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA). The European Commission approved the marketing authorisation for Epidyolex, which contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the €œhigh€ associated with cannabis, for use as adjunctive therapy of seizures associated with Lennox€‘Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. The approval paves the way for the launch of the medicine across Europe. €œThe approval of cannabidiol oral solution is an important milestone for patients and families

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy